Intravitreal triamcinolone versus laser photocoagulation for diabetic macular oedema

Not Applicable

Completed

• Conditions: Diabetes mellitus; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN05040192
• Lead Sponsor: niversity of Malaysia [Universiti Sains Malaysia] (Malaysia)

Brief Summary

2011 results in http://www.ncbi.nlm.nih.gov/pubmed/22111945

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2008-02-01
• Study Start: 2011-04-21
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Diabetic patients
2. Newly diagnosed clinically as DME
3. Aged more than 18 years old
4. Eeither sex

Exclusion Criteria

1. Patients with media opacity impairing intravitreal injection or laser photocoagulation procedure
2. DME with proliferative diabetic retinopathy still undergoing pan retinal photocoagulation
3. History of ocular surgery (eg. cataract operation) or Yag procedure with the risk of further aggravating the macular oedema
4. Intra-ocular pressure greater than 25 mmHg or any established glaucoma patient
5. Ocular or systemic infection
6. Known steroid allergy or responder
7. History of systemic steroid within 4 months prior to randomisation
8. HbA1c more than 10%

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> Measured at 3 months post-procedure:<br> 1. Best Corrected Visual Acuity (BCVA)<br> 2. Macular oedema index<br>

Secondary Outcome Measures

Name	Time	Method
Intraocular pressure, at 3 months post-procedure